CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
复制标题
DOI：
10.1517/14712598.7.8.1257
复制
发表时间：
2007-08-01
影响因子：
4.6
通讯作者：
Morse, Michael A.
中科院分区：
文献类型：
--
作者：
Murad, Yanal M.;Clay, Timothy M.;Morse, Michael A.
Toll 样受体 (TLR)9 的刺激可激活人浆细胞样树突状细胞和 B 细胞，并在临床前肿瘤模型和患者中诱导有效的先天免疫反应。 CpG 寡脱氧核苷 (ODN) 是 TLR9 激动剂，作为疫苗佐剂以及在治疗癌症、感染、哮喘和过敏方面显示出良好的效果。 PF-3512676 (ProMune(R)) 被开发为 TLR9 激动剂，用于治疗癌症，作为单一疗法以及与化疗和免疫疗法联合使用的佐剂。 I 期和 II 期试验已在多种造血系统和实体瘤中测试了该药物。辉瑞已启动 III 期试验，测试 PF-3512676 与标准化疗联合治疗非小细胞肺癌。
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.